Back to first-pass browser

First-pass extracted concept

INHBE

Candidate: concept label1 source documents4 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Evidence Snippets

INHBE was the only protein consistently elevated across all three subgroups.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1candidate biomarkersupports2025Source 1DOIPubMed

INHBE and AFM merit validation as candidate biomarkers and potential contributors to MASLD in postmenopausal women.

Quoted textsource-backed
While exploratory, candidate EV proteins such as INHBE and AFM merit validation as biomarkers and potential contributors to MASLD in this high-risk population.
Claim 2consistency across subgroupssupports2025Source 1DOIPubMed

INHBE was the only protein consistently elevated across all three subgroups.

Quoted textsource-backed
INHBE was the only protein consistently elevated across all three subgroups
Claim 3severity associationsupports2025Source 1DOIPubMed

In severe hepatic steatosis, EV subgroup analysis showed increased COL18A1, AFM, PRG4, and INHBE and decreased C4A and APOA1.

Quoted textsource-backed
In participants with severe hepatic steatosis (n = 43), subgroup analysis showed increased COL18A1, AFM, PRG4, and INHBE and decreased C4A and APOA1.
Claim 4transcriptomic supportsupports2025Source 1DOIPubMed

Hepatic transcriptomic dataset analysis showed consistently higher INHBE expression across the MASLD spectrum, including MASH.

Quoted textsource-backed
Analysis of hepatic transcriptomic datasets demonstrated consistently higher INHBE expression across the MASLD spectrum, including metabolic dysfunction-associated steatohepatitis (MASH)